Insider Activity: James Roach, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)’s insider Unloaded 1,091 Shares

November 23, 2016 - By Linda Rogers

Insider Activity: James Roach, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s insider Unloaded 1,091 Shares

James Roach Insider Sell

A legal document filed with the Security Exchange Commission on 23/11/2016 stated that James Roach, the Senior VP – Development and Chi of Momenta Pharmaceuticals Inc, ‘s company unloaded 1,091 shares. With avg market share price of $13.7 the sale’s sum is $14,911 USD. At present, James Roach owns 155,381 shares which are equivalent to exactly 0.23% of the company’s market capitalization (total value of the shares outstanding).

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Ratings Coverage

Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 26.09% above today’s ($13.57) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, August 6 by Goldman Sachs. Aegis Capital initiated the shares of MNTA in a report on Tuesday, November 22 with “Hold” rating. Goldman Sachs initiated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Monday, June 6. Goldman Sachs has “Neutral” rating and $14 price target. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, October 13 report. Leerink Swann maintained the shares of MNTA in a report on Wednesday, May 4 with “Outperform” rating. On Wednesday, September 7 the stock rating was downgraded by Maxim Group to “Sell”. The company was upgraded on Tuesday, October 11 by Barclays Capital. As per Friday, November 13, the company rating was initiated by JP Morgan. Maxim Group upgraded the shares of MNTA in a report on Friday, January 8 to “Hold” rating. Barclays Capital initiated the shares of MNTA in a report on Monday, November 23 with “Equal-Weight” rating.

Insitutional Activity: The institutional sentiment decreased to 1.35 in 2016 Q2. Its down 0.03, from 1.38 in 2016Q1. The ratio turned negative, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.

Hartford Management Co has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Glenmede Trust Na holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 119 shares. New York State Teachers Retirement has 93,675 shares for 0% of their US portfolio. Blackrock Group holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 83,031 shares. Teachers Advsr has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). The Germany-based Commerzbank Aktiengesellschaft Fi has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). The California-based Aperio Group has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Us Savings Bank De has 0% invested in the company for 3,655 shares. Sector Gamma As reported 914,979 shares or 2% of all its holdings. Capstone Asset Mgmt holds 18,183 shares or 0.01% of its portfolio. Primecap Ca, a California-based fund reported 2.74M shares. South Dakota Council holds 0.04% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 166,960 shares. Wells Fargo & Mn has 0% invested in the company for 173,185 shares. Louisiana State Employees Retirement Sys accumulated 28,000 shares or 0.02% of the stock. Moreover, Clarivest Asset Ltd Liability Com has 0.01% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 32,613 shares.

Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 6 insider sales for $188,231 net activity. WHEELER CRAIG A had sold 5,880 shares worth $70,704. The insider Kaundinya Ganesh Venkataraman sold $12,644. Shea Richard P sold $11,717 worth of stock or 972 shares. $67,600 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares were sold by Shapiro Bennett M. 1,091 shares with value of $13,151 were sold by Roach James M. on Friday, August 19. Another trade for 1,030 shares valued at $12,415 was made by Leicher Bruce on Friday, August 19.

About 132,397 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 37.98% since April 21, 2016 and is uptrending. It has outperformed by 32.65% the S&P500.

Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $899.40 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It currently has negative earnings. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics.

According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”

Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 EPS, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.

MNTA Company Profile

Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>